Viridian Therapeutics, Inc./DE Payment for Debt Extinguishment or Debt Prepayment Cost
Viridian Therapeutics, Inc./DE (VRDN) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2025-03-03
- Viridian Therapeutics, Inc./DE payment for debt extinguishment or debt prepayment cost for the quarter ending 2024-12-31 was $0.00.
- Viridian Therapeutics, Inc./DE payment for debt extinguishment or debt prepayment cost for the quarter ending 2023-12-31 was $0.00.
- Viridian Therapeutics, Inc./DE payment for debt extinguishment or debt prepayment cost for the quarter ending 2022-12-31 was $0.00.
- Viridian Therapeutics, Inc./DE payment for debt extinguishment or debt prepayment cost for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Viridian Therapeutics, Inc./DE payment for debt extinguishment or debt prepayment cost for fiscal 2023 was $514.00K.
- Viridian Therapeutics, Inc./DE payment for debt extinguishment or debt prepayment cost for fiscal 2022 was $0.00.
- Viridian Therapeutics, Inc./DE payment for debt extinguishment or debt prepayment cost for fiscal 2021 was $0.00.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $514.00K 10-K · filed 2025-03-03 | |
| 2023-09-30 | $514.00K 10-Q · filed 2024-11-12 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-13 | ||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |